AFFILIATIONS
1 Changhai Hospital, Shanghai, Shanghai, China, City of Hope National Medical Center, Duarte, California, United States, The Beckman Research Institute of City of Hope, Duarte, California, United States
2 City of Hope National Medical Center, Duarte, California, United States, The Beckman Research Institute of City of Hope, Duarte, California, United States
3 City of Hope National Medical Center, Duarte, California, United States, The Beckman Research Institute of City of Hope, Duarte, California, United States
4 City of Hope National Medical Center, Duarte, California, United States, The Beckman Research Institute of City of Hope, Duarte, California, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 City of Hope National Medical Center, Duarte, California, United States
7 Changhai Hospital, Shanghai, Shanghai, China
8 City of Hope National Medical Center, Duarte, California, United States, The Beckman Research Institute of City of Hope, Duarte, California, United States
ABSTRACT
Introduction:
Dendritic cell subset 3 (DC3) is a distinct CD1c⁺ myeloid population with inflammatory and tissue-remodeling properties, and epiregulin (EREG)-expressing DC3 has been proposed to play an important role in fibrotic disorders and sclerotic graft-versus-host disease (GVHD). Transplantation of G-CSF-mobilized peripheral blood hematopoietic stem cells (PBHSC) is associated with more severe sclerotic GVHD. CD8+ Trm cells were also reported to augment fibrosis. However, the role of DC3 and CD8+ Trm cells in sclerotic GVHD pathogenesis in patients given G-CSF-mobilized PBHSC remains unclear.
Methods:
Peripheral blood mononuclear cells (PBMNC) were collected from patients with sclerotic GVHD, non-sclerotic GVHD, or No-GVHD and healthy control. DC3 were identified by flow cytometry as CD45⁺Lin⁻HLA-DR⁺CD11c⁺CD123⁻CD88⁻CD1c⁺CD163⁺CD5⁻, DC2 were defined as CD1c⁺CD163⁻, and DC1 as CD1c⁻CD141⁺CLEC9A⁺ cells. For functional studies, DC2 and DC3 were sorted from lineage-depleted healthy-donor PBMNC and activated with poly(I:C), R848, and lipopolysaccharide. Activated DC subsets were cocultured with negatively selected autologous T cells for 5 days, followed by assessment of CD103 and CD69 expression in CD8⁺ and CD4⁺ T cells. In paired exploratory samples, circulating pro-DC3 were compared before and after granulocyte colony-stimulating factor (G-CSF) mobilization. Skin tissues of sclerotic GVHD and non-GVHD was subjected to spatial transcriptomic analysis.
Results:
There was a significant increase of CD34⁺CD38⁺CD371⁺ DC3 precursors among donor G-CSF-mobilized PBHSC. Circulating DC3 frequency was significantly increased in patients with sclerotic GVHD compared with patients with Non-sclerotic GVHD or No-GVHD, but the changes in DC1 or DC2 were not significant. In functional coculture assays, as compared with DC2, DC3 induced significantly higher frequency of CD103⁺CD8⁺ T cells and CD103+CD69+CD8+ T cells. Consistently, the frequencies of CD103+CD69+CD8+Trm cells was markedly increased in the sclerotic GVHD skin tissues as compared to non-sclerotic GVHD skin tissues. Spatial transcriptomic analysis of the patient skin tissues with or without sclerotic GVHD is ongoing.
Conclusions:
G-CSF-mobilized PBHSC contains higher frequencies of DC3 precursors in consistency with higher frequencies of DC3 among PBMNC from patients with sclerotic skin GVHD. DC3 preferentially promote CD103⁺CD8⁺ TRM differentiation. These findings support a potential DC3–CD103+CD8⁺ Trm axis in GVHD pathogenesis. Ongoing studies will dissect how circulating and tissue-infiltrating DC3 and CD103+CD8+ Trm cells mediate and sustain sclerotic skin GVHD.
DISCLOSURES
Weijia Fu, MD: No relevant conflicts of interest to declare.